TherapeuticsMD (TXMD)
NASDAQ:TXMD
Want to see TXMD full AI Analyst Report?
TXMD Stock Chart & Stats
$1.68
-$0.07(-6.14%)
At close: 4:00 PM EST
$1.68
-$0.07(-6.14%)
Day’s Range― - ―
52-Week Range$0.98 - $2.95
Previous CloseN/A
Volume92.69K
Average Volume (3M)310.58K
Market Cap
$23.61M
Enterprise Value$21.17M
Total Cash (Recent Filing)$8.42M
Total Debt (Recent Filing)$4.82M
Price to Earnings (P/E)131.9
Beta1.10
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue6.31
Enterprise Value/Gross Profit6.99
Enterprise Value/Ebitda-5.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and positive equity materially reduce solvency risk and give management durable financial flexibility. A stronger balance sheet supports runway for commercialization, R&D or strategic transactions and cushions the business during revenue volatility over the next several months.
Improved Cash GenerationConsistent positive operating and free cash flow increases self-funding capacity and reduces reliance on external financing. Sustained cash generation supports working capital, potential royalty monetization, and preserves strategic optionality even if operating profits remain uneven.
Growing Royalty/License RevenueA structurally larger royalty stream diversifies revenue away from direct product commercialization and lowers operating leverage. An asset-light royalty strategy can produce recurring cash with lower capex and staffing needs, improving margin potential and strategic optionality.
Bears Say
Declining Revenue TrendA persistent top-line decline reduces scale advantages and limits the ability to absorb fixed costs. Over several months this can erode gross profit base, constrain reinvestment, and make current cash-flow improvements harder to sustain without new growth drivers.
Negative Operating ProfitabilityContinued negative operating margins show core commercial operations are not self-sustaining. Even with license revenue and expense cuts, structural unprofitability risks recurrence of losses if revenue weakens, limiting durable earnings power and long-term return on invested capital.
Strategic Alternatives UncertaintyOpen-ended evaluation of M&A, asset sales or other transactions creates prolonged uncertainty around capital allocation and business direction. Lack of clarity can delay investments, complicate partner negotiations, and leave outcomes uncertain for months, affecting execution risk.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.98 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $23.61M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Aug 17, 2026 which is in 75 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on May 18, 2026. The company reported $0.008 earnings per share for the quarter, beating the consensus estimate of N/A by $0.008.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of $0.008 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
4.16% Mutual Funds
24.44% Other Institutional Investors
66.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---